How High Could IBIT Go?
Recently, a surprising number of billionaire hedge fund managers have…
Sell
45
NURO Quote, Financials, Valuation and Earnings
Last price:
$4.44
Seasonality move
:
-6.94%
Day range:
$4.40 - $4.50
52-week range:
$2.66 - $4.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.06x
P/B ratio:
0.57x
Volume:
2.7K
Avg. volume:
6.7K
1-year change:
4.02%
Market cap:
$9M
Revenue:
$5.9M
EPS (TTM):
-$4.24
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, NeuroMetrix has 8929.35% upside to fair value with a price target of -- per share.
NURO vs. S&P 500
-
Over the past 5 trading days, NeuroMetrix has underperformed the S&P 500 by -0.25% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
NeuroMetrix does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
NeuroMetrix revenues have been falling on a year-over-year basis for 7 quarters in a row. In the most recent quarter NeuroMetrix reported revenues of $587.3K.
Earnings Growth
-
NeuroMetrix has grown year-over-year earnings for 1 quarter straight. In the most recent quarter NeuroMetrix reported earnings per share of -$0.75.
Enterprise value:
-5.8M
EV / Invested capital:
--
Price / LTM sales:
2.06x
EV / EBIT:
--
EV / Revenue:
-1.54x
PEG ratio (5yr expected):
-0.10x
EV / Free cash flow:
0.86x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$2.2M
Return On Assets:
-38.57%
Net Income Margin (TTM):
-203.71%
Return On Equity:
-41.7%
Return On Invested Capital:
-41.7%
Operating Margin:
-296.61%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $8.2M | $6.4M | $3.8M | $1.2M | $587.3K | |
| Gross Profit | $5.8M | $4.3M | $2.2M | $781.8K | $312K | |
| Operating Income | -$4.9M | -$6.2M | -$8.7M | -$2M | -$1.7M | |
| EBITDA | -$4.9M | -$6.1M | -$8.5M | -$2M | -$1.7M | |
| Diluted EPS | -$5.52 | -$5.57 | -$4.24 | -$1.66 | -$0.75 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $7.3M | $25.6M | $23.4M | $20.7M | $16.8M | |
| Total Assets | $8.3M | $26.3M | $24M | $21.3M | $17.2M | |
| Current Liabilities | $2.4M | $1.7M | $1.8M | $1.3M | $1.2M | |
| Total Liabilities | $3M | $2.1M | $2.1M | $1.4M | $1.2M | |
| Total Equity | $5.4M | $24.2M | $22M | $19.9M | $16M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$4.3M | -$6.1M | -$6.7M | -$2.1M | -$1.8M | |
| Cash From Investing | -$19M | $3.2M | $3.1M | $1.7M | $1.1M | |
| Cash From Financing | $1.8M | $2.6M | $3.1M | $1.4K | -- | |
| Free Cash Flow | -$4.3M | -$6.3M | -$6.7M | -$2.2M | -$1.8M | |
NURO
Sector
Market Cap
$9M
$36.4M
Price % of 52-Week High
93.66%
44.07%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.03%
1-Year Price Total Return
4.24%
-41.85%
Beta (5-Year)
2.153
0.775
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.49
200-day SMA
Buy
Level
$3.98
Bollinger Bands (100)
Buy
Level
3.91 - 4.41
Chaikin Money Flow
Sell
Level
-14.2M
20-day SMA
Sell
Level
$4.42
Relative Strength Index (RSI14)
Buy
Level
50.97
ADX Line
Buy
Level
40.33
Williams %R
Neutral
Level
-73.3333
50-day SMA
Buy
Level
$4.35
MACD (12, 26)
Buy
Level
0.04
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
94.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-10.9866)
Buy
CA Score
(Annual)
Level (0.268)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (7.6824)
Sell
Piotroski F Score
(Annual)
Level (2)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical equipment and consumables.
Stock Forecast FAQ
In the current month, NURO has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NURO average analyst price target in the past 3 months is --.
-
Where Will NeuroMetrix Stock Be In 1 Year?
According to analysts, the consensus estimate is that NeuroMetrix share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About NeuroMetrix?
Analysts are divided on their view about NeuroMetrix share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that NeuroMetrix is a Sell and believe this share price will drop from its current level to --.
-
What Is NeuroMetrix's Price Target?
The price target for NeuroMetrix over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NURO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for NeuroMetrix is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of NURO?
You can purchase shares of NeuroMetrix via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase NeuroMetrix shares.
-
What Is The NeuroMetrix Share Price Today?
NeuroMetrix was last trading at $4.44 per share. This represents the most recent stock quote for NeuroMetrix. Yesterday, NeuroMetrix closed at $4.42 per share.
-
How To Buy NeuroMetrix Stock Online?
In order to purchase NeuroMetrix stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Raymond James Stock a Buy, Sell or Hold?
Raymond James Financial (NYSE:RJF) is one of America’s large financial…
Is JHX Stock a Buy Sell or Hold?
James Hardie Industries (NYSE:JHX) is a manufacturer of outside building…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
80
CORT alert for Apr 1
Corcept Therapeutics [CORT] is up 109.21% over the past day.
Sell
40
RGC alert for Apr 1
Regencell Bioscience Holdings [RGC] is up 26.1% over the past day.
Buy
74
COOP alert for Apr 1
Mr. Cooper Group [COOP] is up 14.4% over the past day.
